Switch theme
Sign up to access all valuation multiples
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.
2016
n/a
LTM Revenue $44.4M
LTM EBITDA -$19.4M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ABL Bio has a last 12-month revenue of $44.4M and a last 12-month EBITDA of -$19.4M.
In the most recent fiscal year, ABL Bio achieved revenue of $22.8M and an EBITDA of -$36.2M.
ABL Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ABL Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $44.7M | $22.8M | XXX | XXX | XXX |
| Gross Profit | $45.9M | $44.7M | XXX | XXX | XXX |
| Gross Margin | 103% | 196% | XXX | XXX | XXX |
| EBITDA | $1.4M | -$36.2M | XXX | XXX | XXX |
| EBITDA Margin | 3% | -159% | XXX | XXX | XXX |
| Net Profit | $2.2M | -$1.8M | XXX | XXX | XXX |
| Net Margin | 5% | -8% | XXX | XXX | XXX |
| Net Debt | $10.1M | $10.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ABL Bio's stock price is KRW 62200 (or $42).
ABL Bio has current market cap of KRW 2.99T (or $2.0B), and EV of KRW 2.89T (or $2.0B).
See ABL Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $2.0B | XXX | XXX | XXX | XXX | $-0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ABL Bio has market cap of $2.0B and EV of $2.0B.
ABL Bio's trades at 44.4x LTM EV/Revenue multiple, and -101.5x LTM EBITDA.
Analysts estimate ABL Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ABL Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 86.6x | XXX | XXX | XXX |
| EV/EBITDA | -54.5x | XXX | XXX | XXX |
| P/E | -53.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -36.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpABL Bio's NTM/LTM revenue growth is 96%
ABL Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, ABL Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ABL Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ABL Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -49% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -159% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -2635% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -63% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 222% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 278% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ABL Bio acquired XXX companies to date.
Last acquisition by ABL Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . ABL Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ABL Bio founded? | ABL Bio was founded in 2016. |
| Where is ABL Bio headquartered? | ABL Bio is headquartered in South Korea. |
| Who is the CEO of ABL Bio? | ABL Bio's CEO is Mr. Sang-hoon Lee. |
| Is ABL Bio publicy listed? | Yes, ABL Bio is a public company listed on KRX. |
| What is the stock symbol of ABL Bio? | ABL Bio trades under 298380 ticker. |
| When did ABL Bio go public? | ABL Bio went public in 2018. |
| Who are competitors of ABL Bio? | Similar companies to ABL Bio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of ABL Bio? | ABL Bio's current market cap is $2.0B |
| What is the current revenue of ABL Bio? | ABL Bio's last 12-month revenue is $44.4M. |
| What is the current EBITDA of ABL Bio? | ABL Bio's last 12-month EBITDA is -$19.4M. |
| What is the current EV/Revenue multiple of ABL Bio? | Current revenue multiple of ABL Bio is 44.4x. |
| What is the current EV/EBITDA multiple of ABL Bio? | Current EBITDA multiple of ABL Bio is -101.5x. |
| What is the current revenue growth of ABL Bio? | ABL Bio revenue growth between 2023 and 2024 was -49%. |
| Is ABL Bio profitable? | Yes, ABL Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
